TSRA 31.53 Tessera Technologies $TSRA Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 1:49 PM

TSRA 31.53 Tessera Technologies $TSRA Hit a 52 week high of 31.58 Currently at 31.53 -0.03 -0.10% With a day low of 31.25 and a total volume of 17,902.

TSRA Tessera Technologies Recent Headline News

Axcelis Technologies (ACLS) Jumps: Stock Rises 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:04AM CST
Axcelis Technologies Inc. (ACLS) was a big mover last session, as the company saw its shares rise over 7% on the day.
TSRA: 31.76 (+0.20), RTEC: 9.20 (+0.10), MTSN: 2.56 (-0.01), ACLS: 2.13 (unch)

Tessera Technologies Beats on Q3 Earnings & Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:00PM CST
Tessera Technologies Inc. (TSRA) reported strong third-quarter 2014 earnings from continuing operations that jumped from a significant loss in the year-ago quarter and small profit in the previous quarter to sail past the Zacks Consensus Estimate.
AXTI: 2.36 (-0.01), CHTR: 149.37 (-7.00), TSRA: 31.76 (+0.20), SIMO: 23.51 (-0.06)

Tessera Technologies (TSRA) Upgraded From Hold to Buy
at The Street - Mon Nov 03, 8:55AM CST
Tessera Technologies (TSRA) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B+.
TSRA: 31.76 (+0.20)

Tessera posts 3Q profit
Automated Insights - Fri Oct 31, 4:04AM CDT
SAN JOSE, Calif. (AP) _ Tessera Technologies Inc. (TSRA) on Friday reported net income of $108.7 million in its third quarter.
TSRA: 31.76 (+0.20)

TESSERA TECHNOLOGIES
at Investor's Business Daily - Thu Oct 30, 6:13PM CDT
TESSERA TECHNOLOGIES (TSRA), a tech firm, said Q3 EPS grew to 87 cents from last year's Q3 per-share loss of 91 cents, topping by 7 cents. Sales surged 150.4% to $93.3 mil, topping views for $91.9 mil. Shares rose.
TSRA: 31.76 (+0.20)

Tessera Technologies Announces Third Quarter 2014 Results
Business Wire - Thu Oct 30, 3:07PM CDT
--Recurring Revenue Increases 70% to $47.3 Million Year-Over-Year--
TSRA: 31.76 (+0.20)

Can Tessera Technologies' (TSRA) Earnings Surprise in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 4:40PM CDT
Tessera Technologies Inc. (TSRA) is slated to report third-quarter 2014 results on Oct 30.
AMKR: 6.38 (-0.01), TEL: 61.61 (-0.51), TSRA: 31.76 (+0.20), MELI: 136.81 (+2.06)

EMCORE Slumps: EMKR Falls 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:38AM CDT
EMCORE (EMKR) fell nearly 9% in the last trading session amid huge volumes, continuing its recent trend, as the stock is down over 13% in the past one-month time frame.
EMKR: 5.18 (-0.02), COHU: 11.48 (+0.18), TSRA: 31.76 (+0.20), ACLS: 2.13 (unch)

Tessera Technologies to Report Third Quarter 2014 Results on Thursday, October 30
Business Wire - Tue Oct 14, 6:00AM CDT
Tessera Technologies, Inc. (NASDAQ:TSRA) ("Tessera" or the "Company"

will announce its financial results for the third quarter ended September 30, 2014 on Thursday, October 30, 2014, following the close of the market. The Company will host an earnings conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) that same day. During the call, senior management will review the Company's third quarter financial results and business outlook.
TSRA: 31.76 (+0.20)

Amkor Technology Announces Rulings in Tessera Proceedings
Business Wire - Mon Oct 13, 10:59AM CDT
Amkor Technology, Inc. (NASDAQ: AMKR) today announced two rulings in its long-running dispute with Tessera Technologies, Inc. related to a license agreement entered into in 1996 between Tessera and Amkor's predecessor. On October 10, 2014, the Patent Trial and Appeal Board at the United States Patent and Trademark Office, in an inter partes review proceeding, or IPR, ruled on our petition seeking cancellation of certain claims of U.S. Patent No. 6,046,076. In a two-one decision, the IPR board reversed its preliminary determination and denied Amkor's petition with respect to the most material claims. As previously reported, an arbitration panel has awarded Tessera royalties of $113 million plus interest, most of which relate to our alleged use of the '076 patent. The Superior Court for San Francisco County formally confirmed the arbitration panel's award on October 9.
AMKR: 6.38 (-0.01), TSRA: 31.76 (+0.20)

Amkor announces two rulings in dispute proceedings with Tessera
M2 - Mon Oct 13, 8:45AM CDT
A provider of outsourced semiconductor packaging and test services, Amkor Technology Inc (NASDAQ:AMKR) today declared two rulings in its dispute with Tessera Technologies Inc, regarding a license agreement signed in 1996 between Tessera and Amkor's predecessor.
AMKR: 6.38 (-0.01), TSRA: 31.76 (+0.20)

$128.3 Million Judgment Entered by California Court on Tessera's Arbitration Award Against Amkor
Business Wire - Fri Oct 10, 3:05PM CDT
Tessera Technologies, Inc. (NASDAQ: TSRA) ("Tessera" or the "Company"

announced today that a California state court confirmed Tessera, Inc.'s arbitration award and entered judgment of $128,335,504 plus post-judgment interest against Amkor Technology, Inc. ("Amkor"

, and that the U.S. Patent Office confirmed the patentability of key claims in a Tessera patent that Amkor had challenged in an inter partes review ("IPR"

proceeding. The patent was one of several at issue in the arbitration.
AMKR: 6.38 (-0.01), TSRA: 31.76 (+0.20)

First Week of TSRA November 22nd Options Trading
DividendChannel.com - Wed Oct 08, 9:52AM CDT
Investors in Tessera Technologies Inc saw new options begin trading this week, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TSRA options chain for the new November 22nd contracts and...
TSRA: 31.76 (+0.20)

MKS Instruments Poised for Solid Growth, Risks Prevail - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 10:30AM CDT
On Sep 30, 2014, we issued an updated research report on MKS Instruments, Inc. (MKSI). This electric machinery maker primarily serves the semiconductor capital equipment manufacturers.
BRKS: 11.82 (+0.06), TSRA: 31.76 (+0.20), MKSI: 36.62 (+0.49), UTEK: 19.22 (+0.26)

Tessera Technologies (TSRA) Downgraded From Buy to Hold
at The Street - Tue Sep 30, 8:13AM CDT
Tessera Technologies (TSRA) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C.
TSRA: 31.76 (+0.20)

Aixtron SE (AIXG) Jumps: Stock Rises 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:04AM CDT
Aixtron SE (AIXG) was a big mover last session, as the company saw its shares rise almost 9% on the day.
EMKR: 5.18 (-0.02), AIXG: 11.69 (-0.27), BRKS: 11.82 (+0.06), TSRA: 31.76 (+0.20)

Tessera Technologies Names Craig Mitchell as CTO and President of Invensas
Business Wire - Mon Sep 29, 6:00AM CDT
Tessera Technologies, Inc. (NASDAQ:TSRA) ("Tessera" or the "Company"

today announced it has named Craig Mitchell as chief technology officer for Tessera and president of Invensas Corporation, effective immediately. Mr. Mitchell assumes these roles from Simon McElrea, who is leaving the Company for a new opportunity.
TSRA: 31.76 (+0.20)

EMCORE (EMKR) Worth Watching: Stock Soars 25.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:46AM CDT
EMCORE (EMKR) was a big mover last session, with shares surging over 25% on the day.
EMKR: 5.18 (-0.02), BRKS: 11.82 (+0.06), TSRA: 31.76 (+0.20), MKSI: 36.62 (+0.49)

Axcelis Technologies (ACLS) in Focus: Stock Gains 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:25AM CDT
Axcelis Technologies (ACLS) was a big mover last session, with shares rising nearly 9% on the day.
BRKS: 11.82 (+0.06), TSRA: 31.76 (+0.20), MKSI: 36.62 (+0.49), ACLS: 2.13 (unch)

Check Out 5 Hot Stocks Mutual Funds Are Buying Now
at Investor's Business Daily - Fri Sep 19, 7:02AM CDT
What's one sign of solid growth prospects? Institutional ownership. Today's Accelerating Mutual Fund Ownership Screen of the Day features top-rated stocks that have caught the eye of many a mutual fund and have an Accumulation/Distribution Rating of...
GBX: 61.79 (+1.88), TSRA: 31.76 (+0.20), RXN: 28.02 (+0.04), XPO: 38.11 (-0.71), CODE: 20.81 (+0.36)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NOTHING NINE's Global Ambitions: Paris Show's Impact

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Temu Partners with Recyclia to Drive EPR Compliance Boost

Temu and Recyclia: Building a Sustainable Marketplace Get this: Temu, the e-commerce giant you've heard trumpeting about affordable goods like some digital bazaar, is diving deeper into sustainability waters with a partner that knows a thing or two about waste. This time, they've linked up with Recyclia over in Spain. The duo's focus? Helping marketplace sellers meet the...

Medline's Decade-Long WRAP Partnership: More Than Labels

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

SUNON's Approach to AI-Driven Workspaces Debuted at ORGATEC

SUNON's Unique Spin on Future Workspaces The world of workplace solutions is buzzing with ideas on how to blend smart tech with soulful spaces. This year, SUNON is hitting ORGATEC 2026 in Cologne with a bold approach that stitches AI, nature, and circular design right into the fabric of office life. They’re not just setting up shop; they’re promising a peek into a...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

CStone's CS2009: A Leap in Cancer Treatment Validated

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

Air Sealing First: Boosting Home Comfort & Efficiency

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Artprice Champions Creative Freedom with AI in 2026

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Sirha Lyon® 2027: A New Chapter in Foodservice

A Bold Step Forward There's a hearty aroma wafting from Lyon this January, and it's not just from the local gastronomy. Sirha Lyon® is queuing up for its 23rd edition, promising to turn the Foodservice and Hospitality sectors on their heads. Nearly 150,000 square meters of exhibition space packed to the rafters with over 4,300 exhibitors—this ain't your average trade...

OncoHost's Research Links TKI Sensitivity to Biology

Cracking the Code on TKI Sensitivity When it comes to medicine, sometimes the trickiest part is knowing which button to push—especially in the high-stakes world of metastatic renal cell carcinoma (mRCC). OncoHost just dropped a bombshell at the ESMO 2026 Congress about their new plasma proteomics model that lets us peer into what makes some patients click with Tyrosine...